
NRG Oncology Biospecimen Bank

Richard Jordan DDS PhD Nilsa Ramirez, MD Peter Lucas, MD, PhD Jeffry Simko, MD, PhD

NRG Semi Annual Meeting Philadelphia July 2019



NRG Oncology Biospecimen Banks



NRG Oncology Open Trials

	# Open	Target	Accrued	
5/31/2019	Trials	Accrual	Cases	% To Goal
Brain	4	1,017	738	73%
Breast	4	3,586	2,004	56%
GI	5	1,530	605	40%
GU	4	4,122	2,932	71%
GYN	11	3,669	2,405	66%
H&N	3	1,484	623	42%
Lung	5	1,892	285	15%
Sarcoma	1	46	8	17%
TOTAL	37	17,346	9,600	55%



NRGBB Current Inventory

NRGBB Year1-Year 5 (May 31, 2019)	TOTALS
Total Cases (Patients) with Biospecimens	237,155
Total Biospecimens	3,006,048
Total Unique Cases (Patients) Received Years 1-5	15,704
Total Biospecimens Received Years 1-5	253,525
Total Biospecimens Distributed Years 1-5	79,979



As of 5/31/2019

Data Load by NCTN Group into Navigator June 2019

Lead Group	Trials	Specimens
NRG - O	47	475,732
Alliance	35	345,047
SWOG	17	80,619
ECOG-ACRIN	28	64,668
TOTAL	127	966,066



NRGBB Years 1-5 (2015-2019*) Biospecimen Distributions by Organ Site

Disease Site	# Trials	# Specimens	# Patients	
Brain	12	7,721	1,577	
Breast*	6	11,367	6,379	
GI	4	4,291	544	
GU	11	10,020	2,356	
GYN	23	43,398	4,285	
H&N	8	3,182	1,136	
TOTALS for NRG	63	79,979	16,277	




As of 5/31/2019 *Includes specimens distributed for one large project since 2014

NCI NCTN Navigator Requests

(April 2nd 2018- May 31st, 2019)


	LOI				CCSC Proposal						
Disease Site	Submitted ¹	Feasibility Pending	Not Feasible	Feasible	Withdrawn by Investigator	Pending Investigator Submission		Triage Disapproved	Review Pending	Approved ²	Disapproved
Brain	2	0	1	1	0	0	1	0	1	0	0
Breast	6	0	0	6	0	0	6	1	3	2	0
GYN	9	1	2	6	1	3	2	1	1	0	0
GU	9	0	4	5	0	1	4	1	1	2	0
H&N	5	0	1	4	1	1	2	2	0	0	0
Lung	4	0	1	3	0	1	2	1	1	0	0
Colon	4	0	1	3	0	1	1	0	1	0	0
TOTAL	(39)	1	10	(28)	2	7	18	6	8	(4)	0
¹ Includes LOIs re-submitted ² Includes Approval on Hold											







Proposed workflow for CIMACs/CIDC with the clinical networks



- 1. Selection of trials
- 2. Proposal of Biomarker plans will be jointly proposed by CIMAC and Clinical investigators. Requires CTEP (PRC) approval.
- 3. Specimen accession universal tracking system (across biobanks) under discussion.
- 4. Database at CIDC clinical annotation; bioassay results; and sample tracking system
- 5. Data formats and informatics
- 6. Data analysis and publication Primary analysis: With trial investigators;



CIMAC TRIALS AND NRGBB

- Example of basic CIMAC requirement for NRG Trials:
- Regular FFPE Collection: H&E slide and block
 - Bank cuts and distributes slides for IHC
 - Bank extracts DNA/RNA from slides (extractions should be done by CIMAC to standardize this)
- Streck Tubes- for cell free DNA. 3 Timepoints per study
 - Sites collect, ship to bank, bank processes.
 - Bank distributes specimens to CIMAC
- Heparin Tubes for PBMCs and Plasma. 3 Timepoints per study
 - Sites collect, ship to bank, bank processes
 - Bank distributes specimens to CIMAC. 1 Timepoint per study
- Whole Blood for DNA
 - Sites collect, ship to bank, bank aliquots.
 - Bank distributes specimens to CIMAC



Est. Collection and Distribution Cost Per Case: \$2200